ALK and non-small cell lung carcinoma: Considering the limitations associated with crizotinib therapy in terms of resistance and inadequate effect on brain metastases, ceritinib offers a favorable treatment option for first-line treatment of ALK + NSCLC with the potential to improve outcomes and prolong survival.